Screener
Seres Therapeutics MCRB Q1 2026 earnings
Reported May 5, 2026 · Before market open
Revenue$358.0KIn line
EPS-$2.08Miss by $0.20
Revenue estimate$358.0K
EPS estimate-$1.88
Next report
Nov 4, 2026 (in 2 months)Revenue estimate$6.4M
EPS estimate-$1.01
Versus estimates
Revenue
Q2 2026$736.0KBeat by $557.0K
Q1 2026$358.0KIn line
Q4 2025$438.0KMiss by $4.9MQ3 2025$351.0KMiss by $7.5MDiluted EPS
FAQ
- When did Seres Therapeutics report Q1 2026 earnings?
- Seres Therapeutics (MCRB) reported Q1 2026 earnings on May 5, 2026 before market open.
- What were Seres Therapeutics's Q1 2026 revenue and EPS?
- Seres Therapeutics reported revenue of $358.0K and eps of $-2.08 for Q1 2026.
- Did Seres Therapeutics beat estimates in Q1 2026?
- Revenue beat the consensus estimate of $358.0K by -. EPS missed the consensus estimate of $-1.88 by $0.20.
- How did Seres Therapeutics's Q1 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 7.1% from $-2.24.
- Where can I find Seres Therapeutics's Q1 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-205009) and the 10-Q periodic report (0001193125-26-205434) directly on SEC EDGAR. The filing index links above go to sec.gov.
